Introduction
Breast cancer continues to be the second leading cause of cancer-related deaths among women worldwide. Approximately 70% of breast cancers are estrogen receptor α-positive (ERα
+) and progesterone receptor-positive (PR
+). They are divided into two subtypes: luminal A, comprising those that are negative for the overexpression or gene amplification of
ErbB-2/HER2 and have low levels of genes responsible for proliferation, and luminal B, comprising those that are positive for
HER2 and have high expression of proliferation-associated genes [
1,
2]. This division is in part due to their sensitivity to antihormonal therapy such as tamoxifen or an aromatase inhibitor. The luminal A subtype carries the best prognosis, followed by luminal B. The third subtype is ER
-/PR
- and HER2
+, which contains gene amplification for the
ErbB-2/HER2 oncogene. The HER2
+ subtype represents 15% to 25% of breast cancers and is currently treated with trastuzumab plus a taxane-based chemotherapy. The HER2
+ subtype of breast cancer is associated with excellent survival outcomes due to adjuvant trastuzumab therapy, a humanized monoclonal antibody that targets the HER2 receptor [
3]. However, 30% to 60% of metastatic HER2
+ breast cancer are resistant to trastuzumab. The fourth subtype of breast cancer is the normal-like subtype, which resembles normal mammary epithelial cells expressing genes associated with adipose tissue. The fifth subtype represents 15% of breast cancers and is triple-negative, and thus lacks expression of ER/PR and HER2. Triple-negative breast cancers carry the worst prognosis because of the lack of US Food and Drug Administration-approved targeted therapies [
4,
5]. Thus, there is an immediate need for the elucidation of novel targets to treat women with triple-negative breast cancer and to increase these patients' overall survival.
Notch signaling has emerged as a target for the treatment of breast cancer [
6]. In the mammalian system, there are four Notch receptors (Notch-1, Notch-2, Notch-3 and Notch-4) [
7] and five known ligands (Delta-like 1, Delta-like 3 and Delta-like 4 and Jagged-1 and Jagged-2) [
8‐
10]. Cell-to-cell contact is critical for the activation of Notch signaling, which subsequently enables the pathway to modulate genes involved in cell fate such as proliferation or differentiation [
11]. Notch is processed in the trans-Golgi apparatus, where it undergoes the first of three proteolytic cleavages. The single polypeptide is cleaved (S1) by furin-like convertase forming the mature Notch receptor, which is a heterodimer consisting of Notch extracellular (NEC) and Notch transmembrane (NTM). The receptor is trafficked to the plasma membrane, where it awaits engagement with its membrane-associated ligand. Upon ligand-receptor engagement, the second cleavage (S2) by a disintegrin and metalloproteases 10 and 17 (ADAM10 and ADAM17, respectively) [
12] releases NEC to be endocytosed into the ligand-expressing cell. Subsequently, NTM is cleaved (S3) by the γ-secretase complex, liberating the intracellular portion of Notch (NIC) [
13]. NIC translocates to the nucleus and binds to CBF-1, a constitutive transcriptional repressor, displacing corepressors and recruiting coactivators such as Mastermind [
14,
15]. Notch activates many genes associated with differentiation and/or survival, including, but not limited to, the HES and HEY family of basic helix-loop-helix transcription factors [
16], cyclin D1 [
17] and c-Myc [
18]. The third and final cleavage step is critical for active Notch signaling. Its inhibition can be exploited through emerging pharmacological drugs identified as γ-secretase inhibitors (GSIs), which attenuate signaling from all four receptors. Recent studies have demonstrated that GSI treatment suppresses breast tumor growth in a variety of breast cancer subtypes [
19‐
23], providing evidence of novel therapeutic approaches.
The first evidence that Notch receptors are breast oncogenes was provided by mouse studies. Overexpression of constitutive, active forms of Notch-1 (N1IC) or Notch-4 (N4IC) form spontaneous murine mammary tumors
in vivo [
11]. Furthermore, elevated expression of Notch-1 and/or its ligand Jagged-1 in human breast tumors is associated with the poorest overall patient survival [
24‐
26]. Recently, Notch-4 has been shown to be critical for the survival of tumor-initiating cells [
27]. Similarly to studies performed using Notch-1, mouse mammary tumor virus (MMTV)-driven Notch-3 receptor intracellular domain expression in transgenic mice showed enhanced mammary tumorigenesis [
28]. In HER2
- breast cancers, downregulation of Notch-3 resulted in suppressed proliferation and increased apoptosis [
29]. In contrast, overexpression of Notch-2 in MDA-MB-231 cells significantly decreased tumor growth and increased apoptosis in vivo [
30], suggesting that Notch-2 is a breast tumor suppressor.
The factors that regulate Notch receptor expression in breast cancer cells are still widely unknown. It has been shown that p53 binds to the Notch-1 promoter and activates Notch-1 receptor transcription in human keratinocytes [
31]. Activator protein 1 (AP-1) has been demonstrated to be a transcriptional activator of Notch-4 in human vascular endothelial cells [
32]. We asked which factors regulate Notch receptor transcription in breast cancer.
Polyomavirus enhancer activator 3 (PEA3/E1AF/ETV4) is a member of the ETS family of transcription factors, which also includes ERM and ER-81. PEA3 is overexpressed in metastatic breast carcinomas, particularly triple-negative breast tumors [
33]. PEA3 regulates critical genes involved in inflammation and invasion, such as IL-8 [
34], cyclooxygenase-2 (COX-2) [
35] and matrix metalloproteases (MMPs) [
36‐
39]. A dominant-negative form of PEA3 reduced tumor onset and growth in a MMTV/
neu-transgenic model of breast cancer
in vivo [
40]. PEA3 contains an ETS winged helix-turn-helix DNA binding motif [
41] that binds to the canonical sequence GGAA/T on target genes [
42]. The affinity of binding relies on proximal sequences surrounding the ETS binding site which aid in transcriptional control based on context [
43]. Phosphorylation of serine and threonine residues by the mitogen-activating protein kinase cascade activates PEA3 and is negatively regulated by the ubiquitin-proteasome pathway as well as by sumoylation [
44‐
46].
The transcriptional activity of PEA3 is dependent on other activators to regulate gene transcription and is commonly partnered with AP-1 to regulate genes such as MMP-1, MMP-3, MMP-7 and MMP-9 [
36]; urokinase-type plasminogen activator (uPA) [
47]; COX-2 [
35]; and ErbB-2 [
48]. AP-1 is a dimeric complex consisting of the Fos (c-FOS, FosB, Fra-1 and Fra-2) and Jun (c-JUN, JunB and JunD) families [
49]. Depending on the cellular context, AP-1 cooperates with other proteins including, but not limited to, NFκB, CBP/p300, Rb and PEA3 [
50,
51]. The functional role of AP-1 is to recruit and direct appropriate factors to regulate gene expression and promote proliferation, differentiation, inflammation and/or apoptosis [
52].
Previous investigations have determined that overexpression of Notch-1 and Notch-4 plays a critical role in breast tumorigenesis [
11] and that PEA3 overexpression is associated with aggressive breast cancers, particularly the triple-negative subtype [
53‐
58]. Herein we provide novel evidence of a link between two pathways that are overexpressed in breast cancer. PEA3 is a transcriptional activator of Notch-1 and Notch-4 and a repressor of Notch-2 in MDA-MB-231 cells, an example of triple-negative breast cancer cells. PEA3-mediated Notch-1 transcription is AP-1-independent, while Notch-4 transcription requires both PEA3 and c-JUN. PEA3 and/or Notch signaling are essential for proliferation, survival and tumor growth of MDA-MB-231 cells. Furthermore, PEA3 is a transcriptional activator of both Notch-1 and Notch-4 in other breast cancer cells. Thus we hypothesized that targeting of the PEA3 and/or Notch pathways might provide a new therapeutic strategy for triple-negative breast cancer as well as possibly other breast cancer subtypes where PEA3 regulates Notch-1 and/or Notch-4.
Materials and methods
Cell culture and reagents
MDA-MB-231, SKBr3, BT474 and MCF-7 breast cancer cells were purchased from the American Type Culture Collection (Manassas, VA, USA). All cell lines were supplemented with 100 μmol nonessential amino acids and 1% L-glutamine. SKBr3 cells (supplemented with 10% fetal bovine serum (FBS)) and MDA-MB-231 cells (supplemented with 5% FBS) were maintained in Iscove's Minimal Essential Medium (IMEM). MCF-7 cells (supplemented with 10% FBS) were maintained in DMEM/Ham's Nutrient Mixture F-12. BT474 cells (supplemented with 10% FBS) were maintained in DMEM. All cells were cultured in a 37°C incubator with 5% CO2. MRK-003 GSI was kindly provided by Merck Oncology International, Inc. (33 Avenue Louis Pasteur, Boston, MA, USA). MRK-003 GSI was dissolved in dimethylsulfoxide (DMSO) and stored at -80°C until use. Lactacystin (L6785) was purchased from Sigma-Aldrich (St Louis, MO, USA), dissolved in deionized water and stored at -20°C until use. The pcDNA3.1 expression vector and the PEA3-pcDNA3.1 expression vector were kindly provided by Dr Mein-Chie Hung (The University of Texas MD Anderson Cancer Center, Houston, TX, USA). The pHMB empty and pHMB-TAM-67 expression vectors were kindly provided by Dr Richard Schultz, Department of Immunology and Microbiology, (Loyola University Medical Center, Maywood, IL, USA).
RNA interference and reagents
Control scrambled siRNA-a (sc-37007), Notch-1 siRNA (sc-36095), and a smart pool of three distinct PEA3 siRNA (PEA3ia, sc-36205) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). An unrelated control siRNA and PEA3 siRNA (PEA3ib, catalog number 115237) were purchased from Ambion (Austin, TX, USA). A smart pool of four distinct c-Jun siRNA (sc-29223) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Transfection reagents used were Lipofectamine 2000 and Lipofectamine RNAiMAX, which were purchased from Invitrogen (Carlsbad, CA, USA), and FuGENE 6 was purchased from Roche Diagnostics Corporation (Indianapolis, IN, USA). Protocols were performed as described by the manufacturers.
Antibodies
Notch-1 (antibody clone C-20), Notch-4 (antibody clone H-225), PEA3 [
16] (product number sc-113), c-JUN (antibody clone G-4) were purchased from Santa Cruz Biotechnology. β-actin (antibody clone AC-15) was purchased from Sigma-Aldrich and used as the loading control
Real-time RT-PCR
Total RNA was extracted from the cells using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's protocol. Total cDNA was reverse-transcribed from the total RNA with random hexamers using the MultiScribe™ Reverse Transcriptase Kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's protocol. Analysis of transcript relative fold copy number adjusted to hypoxanthine-guanine phosphoribosyl transferase (HPRT), an endogenous control, was carried out by quantitative real-time PCR using iTaq™ SYBR Green Supermix with ROX (Bio-Rad Laboratories, Hercules, CA, USA) and the PlusOne thermal cycler from Applied Biosystems. The following primers were used for detection: Notch-1 (forward primer: 5'-GTCAACGCCGTAGATGACC-3', reverse primer: 5'-TTGTTAGCCCCGTTCTTCAG-3'), Notch-2 (forward primer: 5'-TCCACTTCATACTCACAGTTGA-3', reverse primer: 5'-TGGTTCAGAGAAAACATACA-3'), Notch-3 (forward primer: 5'-GGGAAAAAGGCAATAGGC-3', reverse primer: 5'-GGAGGGAGAAGCCAAGTC-3'), Notch-4 (forward primer: 5'-AACTCCTCCCCAGGAATCTG-3', reverse primer: 5'-CCTCCATCCAGCAGAGGTT-3'), PEA3 (forward primer: 5'-AGGAGACGTGGCTCGCTGA-3'), (reverse primer: 5'-GGGGCTGTGGAAAGCTAGGTT-3'), HEY-1 (forward primer: 5'-TGGATCACCTGAAAATGCTG-3', reverse primer: 5'-TTGTTGAGATGCGAAACCAG-3'), MMP-9 (forward primer: 5'-TCGTGGTTCCAACTCGGTTT-3', reverse primer: 5'-GCGGCCCTCGAAGATGA-3') and IL-8 (forward primer: 5'-CACCGGAAGGAACCATCTCACT-3', reverse primer: 5'-TCAGCCCTCTTCAAAAACTTCTCC-3'), with HPRT (forward primer: 5'-ATGAACCAGGTTATGACCTTGAT-3', reverse primer: 5'-CCTGTTGACTGGTCATTACAATA-3') used as the loading control. Protocols were performed as described by the manufacturers. Transfection conditions for Western blot analysis and RT-PCR were as follows. MDA-MB-231 (4 × 105), MCF-7 (4 × 105), SKBr3 (5 × 105) and BT474 (5 × 105) cells were placed into a six-well culture dish. Twenty-four hours later the cells were transfected with reagents. Forty-eight hours later cells were harvested and protein/RNA was extracted. Notch-4 luciferase constructs were generously provided by Dr Emery Bresnick, Cell & Regenerative Biology, (University of Wisconsin at Madison, Madison, WI, USA). The AP-1 luciferase construct was generously provided by Dr Richard Schultz, Department of Immunology and Microbiology,(Loyola University Medical Center, Maywood, IL, USA). Dual-luciferase assays were performed as described by the manufacturer (Promega, Madison, WI, USA). A pRL-thymidine kinase promoter-driven Renilla luciferase reporter was cotransfected with the Firefly luciferase construct mentioned above as an internal transfection control. Transfection activity was measured using the Veritas Microplate Luminometer (Turner Biosystems, Sunnyvale, CA, USA) and represented as the ratio of Firefly luciferase to Renilla luciferase.
Western blot analysis
The cells were lysed in radioimmunoprecipitation assay buffer (pH 8.0) containing 50 mmol Tris HCl, 150 mmol NaCl, 1% Nonidet P-40 (NP-40), 0.5% sodium deoxycholate, 0.1% SDS, 25 mmol β-glycerophosphate, 1 mmol sodium orthovanadate, 1 mmol sodium fluoride, 1 mmol phenylmethylsulfonyl fluoride, 1 mg/mL aprotinin and 1 mg/mL leupeptin. Western blot analysis was performed as previously described [
21]. NuPAGE Bis-Tris Gels (4% to 12%; Invitrogen) in 3-(N-morpholino)propanesulfonic acid buffer were run at 175 V for 1.5 hours, and proteins were transferred at 38 V for 2 hours using polyvinylidene fluoride membranes. Protein detection was performed using the SuperSignal West Dura Substrate (Thermo Scientific, Rockford, IL, USA) and visualized by using the FUJIFILM™ Las-300 imager (GE-Healthcare Bio-Sciences, Piscataway, NJ, USA).
Chromatin immunoprecipitation
MDA-MB-231 cells (3 × 106) were plated in 150-cm2 Petri dishes. Twenty-four hours later cells were transfected with pcDNA3.1, PEA3-pcDNA3.1 and PEA3-pcDNA3.1, together with PEA3 siRNA, for 48 hours. The cells were cross-linked with 1% formaldehyde and lysed in SDS lysis buffer (1% SDS, 10 mmol ethylenediaminetetraacetic acid (EDTA), 50 mmol Tris HCl, pH 8.1). The lysates were sonicated using the Branson Sonifier model 250 (Branson Ultrasound Corp., Danbury, CT, USA) at output 4.5, duty cycle 50, and pulsed 10 times. The lysate was then diluted 1:10 in immunoprecipitation dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mmol EDTA, 16.7 mmol Tris HCl, 167 mmol NaCl, pH 8.1). Approximately 300 to 700 μg of total precleared protein in lysates were incubated with 4 μg of PEA3 antibody (sc-113X; Santa Cruz Biotechnology) or mouse immunoglobulin G (IgG) overnight. Fifty microliters of protein G-plus agarose beads (sc-2002; Santa Cruz Biotechnology) were added to the immune complexes for 2 hours while gently rocking. Immune complexes/beads were washed in low-salt buffer (0.1% SDS, 1% Triton X-100, 2 mmol EDTA, 20 mmol Tris HCl, 150 mmol NaCl, pH 8.1), high-salt buffer (0.1% SDS, 1% Triton X-100, 2 mmol EDTA, 20 mmol Tris HCl, 500 mmol NaCl, pH 8.1), LiCl buffer (1% sodium deoxycholate, 1% NP-40, 0.25 mol LiCl, 1 mmol EDTA, 10 mmol Tris HCl, pH 8.1) and Tris-EDTA buffer (1 mmol EDTA and 10 mmol Tris HCl) at 4°C with agitation. The protein/antibody complexes from beads were eluted in freshly prepared elution buffer (1% SDS, 0.1 mol sodium bicarbonate, pH 8.0). Cross-linking of proteins and DNA was reversed by heating at 65°C overnight while gently rocking. The protein was degraded using a proteinase solution (0.5 mol EDTA, 1 M Tris HCl, pH 8.0, 10 mg/mL proteinase K) and incubated at 52°C for 1 hour. DNA was isolated using the QIAquick PCR purification kit (Qiagen). Enrichment at promoter sites was detected by quantitative PCR using iTaq™ SYBR Green Supermix with ROX (Bio-Rad Laboratories). Ct threshold values were normalized to the IgG control. The following promoter region primers were used in detection: Notch-1 promoter regions not containing ETS or AP-1 sequences served as negative controls (forward primer: 5'-GTGCACACGGCTGTCCG-3', reverse primer: 5'-GCGACAACTGGCGACTGAA-3'), 2× PEA3 (forward primer: 5'-GCTGCAAGAGCCAAGATGAA-3', reverse primer: 5'-GGTGCCTGTGTTGAAAGCTCT-3'), c-ETS (forward primer: 5'-CTCCTGGCGCTTAACCAGG-3', reverse primer: 5'-CCAGAAAGCACAAACGGGTC-3'), AP-1(A) (forward primer: 5'-GCCTCCTTAGCTCACCCTGA-3'), reverse primer (5'-TCTTCAGAGGCCCCCTGC-3'), AP-1(B) (forward primer: 5'-TCCGCAAACCAGGCTCTG-3', reverse primer: 5'-ATTGGGGTGCAGTGCCG-3'), Sp-1/PEA3 (forward primer: 5'-CACCTCGACTCTGAGCCTCAC-3', reverse primer: 5'-CTCTTCCCCGGCTGGCT-3'). Notch-4 promoter regions not containing ETS or AP-1 sequences served as negative controls (forward primer: 5'-GGCGAGGATTCTAATGTGGA-3', reverse primer: 5'-CCCTGA GTGAAAGGGTGAAG-3'), CBF-1 (forward primer: 5'-TGGTACCACCCTGGTCAGTAT-3', reverse primer: 5'-TGCTCAGGCATTATGAGCTATG-3'), AP-1(A) (forward primer: 5'-AGCTGCCACTGACACCTTCT-3', reverse primer: 5'-CAGGGAATGCCAGTCAGAAT-3'), AP-1(B) (forward primer: 5'-ACTTCCCCAGGGGTTGTC-3', reverse primer: 5'-CTTCCTCCTCGGCCTGCT-3') and PEA3/ETS (forward primer: 5'-GGGTTCCTCTTCCCCATACC-3', reverse primer: 5'-TCATTTTCCCATCACCTTCCTT-3').
Coimmunoprecipitation
MDA-MB-231 cells (3 × 106) were plated in 150-cm2 Petri dishes for 24 hours. The cells were transfected with pcDNA3.1, PEA3-pcDNA3.1 and PEA3-pcDNA3.1, together with PEA3 siRNA, for 48 hours. The cells were cross-linked with 1% formaldehyde and lysed in SDS lysis buffer (1% SDS, 10 mmol EDTA, 50 mmol Tris HCl, pH 8.1). The lysates were sonicated using the Branson Sonifier 250 at output 4.5, duty cycle 50, and pulsed 10 times. The lysate concentration was ascertained and was equally diluted in immunoprecipitation dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mmol EDTA, 16.7 mmol Tris HCl, 167 mmol NaCl, pH 8.1). Approximately 300 to 700 μg of total precleared lysates were incubated with 3 μg of PEA3 antibody (sc-113X; Santa Cruz Biotechnology) or mouse IgG overnight. Thirty microliters of protein G-plus agarose beads (sc-2002, Santa Cruz Biotechnology) were added to the immune complexes for 2 hours while gently rocking. Immune complexes and beads were washed three times in PBS. The pellet was resuspended in Laemmli sample buffer with 5% β-mercaptoethanol (Bio-Rad Laboratories) and heated for 5 minutes at 95°C while vigorously shaking. Western blot analysis was used to detect coimmunoprecipitation proteins as described above. Antibodies used for detection were PEA3 (16), c-FOS (H-125), c-JUN (G-4) and Fra-1 (R-20).
Cell cycle analysis
MDA-MB-231 cells (1 × 105) were seeded into a six-well plate. After 24 hours, the cells were treated/transfected with DMSO/scrambled, control siRNA, DMSO/PEA3 siRNA, MRK-003 (10 μmol)/scrambled siRNA or MRK-003 (10 μmol)/PEA3 siRNA. Briefly, 24 and 48 hours posttreatment/posttransfection, the cells and media were isolated and permeabilized with 70% ethanol. The cells were then pelleted, washed in 5% bovine calf serum and resuspended in 10 μg/mL RNase/PBS solution. The cells were stained with propidium iodide (100 μg/mL) and analyzed by flow cytometry (FACSCanto; BD Biosciences, San Jose, CA, USA).
Annexin V
MDA-MB-231 cells (1.5 × 105) were seeded into a six-well plate for 24 hours. Cells were treated/transfected with DMSO/scrambled siRNA, DMSO/PEA3 siRNA, MRK-003 (10 μmol)/scrambled siRNA and MRK-003 (10 μmol)/PEA3 siRNA. Briefly, after 24 and 48 hours of treatment/transfection, 1 × 106 cells were isolated in 1× annexin binding buffer (0.1 mol 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid/NaOH, 140 mol NaCl, 25 mmol CaCl2, pH 7.4) and treated with both fluorescein isothiocyanate-annexin V stain and propidium iodide. After 1-hour incubation, the samples were subjected to analysis by flow cytometry (FACSCanto; BD Biosciences).
Cell viability assay
MDA-MB-231 cells (1.5 × 105) were seeded into a six-well plate for 24 hours. Cells were treated/transfected with DMSO/scrambled siRNA, DMSO/PEA3 siRNA, MRK-003 (10 μmol)/scrambled siRNA and MRK-003 (10 μmol)/PEA3 siRNA. Briefly, after 24 and 48 hours of treatment/transfection, cells and media were harvested and washed in PBS. The cells were stained with trypan blue and counted under a standard slide microscope at ×40 magnification.
In a six-well plate, a bottom layer of 1 mL of 0.8% agar dissolved in IMEM was added. Two milliliters of a 2% methylcellulose/IMEM solution (supplemented with 5% FBS, 1% nonessential amino acids and 1% L-glutamine) were added on top of the agar. MDA-MB-231 cells (1 × 103 cells/mL) were treated/transfected with DMSO/scrambled siRNA, DMSO/PEA3 siRNA, MRK-003 (5 μmol)/scrambled siRNA or MRK-003 (5 μmol)/PEA3 siRNA for 24 hours. Treated cells were added directly to the methylcellulose solution. The assay was left untouched for 14 days at 37°C and 5% CO2. Colonies were stained with crystal violet for 1 hour, photographed and counted under a standard light microscope at ×40 magnification. Nine fields per well were counted.
MDA-MB-231 xenograft study
MDA-MB-231 cells were transfected in vitro with control or PEA3 siRNA smart pool for 24 hours as described previously. One million cells were subsequently injected into each of two mammary fat pads of 10 Balb/c athymic nude mice per group, for a total of 40 mice. The mice were randomized to control siRNA or PEA3 siRNA and fed orally by gavage, vehicle control (2% carboxymethylcellulose in sterile PBS) or 100 mg/kg MRK-003 GSI for three consecutive days per week. The tumor areas were measured using vernier calipers, and growth rates were calculated by linear regression analysis. The tumor areas were monitored biweekly for up to 3.5 weeks. The protocols used to study breast tumor xenografts in mice were approved by Loyola University's Institutional Animal Care and Use Committee.
Discussion
PEA3 was originally identified as a member of the ETS family of transcription factors. Since then, it has been observed that PEA3 is expressed during normal breast development, is quickly lost upon maturation and yet reemerges in metastatic breast cancers [
33,
54,
61,
66‐
68]. Similarly, Notch has been implicated in breast cancer, demonstrating elevated expression and activity in breast tumors [
25,
26]. Little is known about the factors that influence
Notch gene expression and why its levels are elevated in breast cancer. Herein we provide the first evidence of transcriptional regulation of
Notch-1 and
Notch-4 by PEA3 in MDA-MB-231 and other breast cancer subtypes (Figures
1 through 3). We have demonstrated that
Notch-4 gene regulation is dependent on AP-1 factors such as c-Jun, Fra-1, c-Fos and now PEA3, depending on cellular context (Figures
5 and
7). Interestingly, we provide evidence that c-Jun and Fra-1 are transcriptional activators of
Notch-4, but that c-FOS could be a transcriptional repressor of
Notch-4 (Figure
7). PEA3 regulates the
Notch-1 promoter, but the additional factors that aid in that regulation are still being investigated. Further evidence reveals that PEA3 inhibition helps sensitize MDA-MB-231 cells to a GSI, showing promise in significantly reducing both anchorage-dependent and anchorage-independent growth as well as increasing apoptosis
in vitro (Figures
8,
9A and
9B). Moreover, PEA3 expression or Notch activity is required for optimal growth of MDA-MB-231 tumors
in vivo (Figure
9C). Thus, PEA3 emerges as a potential target, possibly upstream of Notch activity, for triple-negative cancer and possibly other breast cancer subtypes where PEA3 and/or Notch activities are critical for growth. This was evident in the preclinical model of our MDA-MB-231 xenograft study (Figure
9C). Either PEA3 knockdown or GSI treatment was adequate to significantly inhibit tumor growth
in vivo. This result could suggest that targeting PEA3, a transcriptional activator of Notch-1 and Notch-4, hits multiple targets at once. For example, PEA3 is an activator of
MMPs [
36‐
39,
53],
uPAR [
55,
56],
COX-2 [
35] and now
Notch-1 and
Notch-4. PEA3 expression and Notch signaling could be critical for tumor formation and communication with the tumor microenvironment, which is not possible to recapitulate
in vitro using single-cell suspensions. The severe side effects associated with GSI treatment, such as gastrointestinal toxicity [
69,
70], could possibly be avoided if inhibition of PEA3 is able to inhibit several growth- and metastasis-promoting signaling pathways.
Notch is a cellular fate determinant and can induce cell proliferation and/or differentiation, depending on the cellular environment [
71]. PEA3 has been linked to the invasion, migration and aggressiveness of tumor cells [
33,
40,
53,
54,
57,
61,
67,
68,
72,
73]. The dual or individual inhibition of Notch by the GSI, and the inhibition of PEA3 by siRNA, acts by preventing two vital arms of cancer progression, namely, growth and possibly invasion, which we are currently investigating
in vitro and
in vivo. Emerging nanotechnology can be used as a means by which to direct siRNA therapies [
74], and the advent of stapled interface peptides [
75] that disrupt transcription factor complexes transforms the notion of specific targeting of the PEA3 transcription factor into a potential reality.
In addition, Harrison
et al. [
27] implicated Notch-4 in mammary tumor stem cell survival and self-renewal in a recent study in which they demonstrated that targeting Notch-4 specifically was more effective than a targeting a GSI in inhibiting the Notch pathway. In our studies, we found that Notch-4 gene transcription was more sensitive to PEA3 inhibition. Given this fact, the sensitivity that we obtained in our MDA-MD-231 system by the dual inhibition using a PEA3 siRNA in combination with MRK-003 GSI reduced viability and increased apoptosis may be explained by the notion that we may have targeted not only the proliferation and survival of bulk cancer cell populations but also possibly the cancer stem cell population.
Herein we have provided evidence of a novel therapeutic strategy to be exploited for the treatment of triple-negative breast cancer and potentially other breast cancer subtypes where PEA3 regulates Notch-1 and Notch-4. Enhanced sensitivity toward current GSIs or alternative strategies for future clinical trials by inhibition of PEA3 by nanoparticles, small-molecule inhibitors or future siRNA approaches may increase patient response to treatment and could reduce or eliminate recurrence if stem cell populations are eliminated. Inhibiting PEA3 may also allow for a larger therapeutic window for GSI treatment, enabling the reduction of pharmacological doses or possibly eliminating the need for the GSI if PEA3 is indeed upstream of Notch signaling, thus lowering resultant undesirable side effects such as gastrointestinal toxicity and possibly skin cancer.
Competing interests
AGC and CO declare that there is a patent pending on the identification of PEA3 as a biomarker for sensitivity to GSIs in breast tumors and possibly other solid tumors in conjunction with work conducted with the MRK-003 GSI developed by Merck Oncology International, Inc. We declare that there are no other financial conflicts of interest besides the patent application.
Authors' contributions
AGC performed the majority of the experiments and wrote the manuscript. AR and KP injected MDA-MB-231 cells into mice, fed mice MRK-003 orally by gavage and assisted in tumor area measurements and statistical calculations. LM is a co-principal investigator on CO's US Department of Defense award and provided reagents and critical expertise. All authors read and approved the final manuscript.